ATE465738T1 - Neue kristalline formen der krebsbekämpfenden verbindung zd1839 - Google Patents

Neue kristalline formen der krebsbekämpfenden verbindung zd1839

Info

Publication number: ATE465738T1
Authority: AT; Austria
Prior art keywords: solvate; compound; trihydrate; occurs; designated
Prior art date: 2002-02-26

Application number

AT03708319T

Other languages

English (en)

Inventor

John Gilday

Anthony Graham

Bo Ymen

Martin Bohlin

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-02-26

Filing date

2003-02-24

Publication date

2010-05-15

2002-02-26 Priority claimed from GB0204392A external-priority patent/GB0204392D0/en

2002-05-30 Priority claimed from GB0212462A external-priority patent/GB0212462D0/en

2003-02-24 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2010-05-15 Application granted granted Critical

2010-05-15 Publication of ATE465738T1 publication Critical patent/ATE465738T1/de

Links

150000001875 compounds Chemical class 0.000 title abstract 3
206010028980 Neoplasm Diseases 0.000 title 1
201000011510 cancer Diseases 0.000 title 1
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 abstract 6
239000012453 solvate Substances 0.000 abstract 6
238000004519 manufacturing process Methods 0.000 abstract 2
150000004684 trihydrates Chemical class 0.000 abstract 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 abstract 1
UZILUDOSEVNVMU-UHFFFAOYSA-N N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine methylsulfinylmethane Chemical compound ClC=1C=C(NC2=NC=NC3=CC(=C(C=C23)OCCCN2CCOCC2)OC)C=CC1F.CS(=O)C UZILUDOSEVNVMU-UHFFFAOYSA-N 0.000 abstract 1
-1 ZD1839 trihydrate Chemical class 0.000 abstract 1
230000001028 anti-proliverative effect Effects 0.000 abstract 1
238000006243 chemical reaction Methods 0.000 abstract 1
229960001760 dimethyl sulfoxide Drugs 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
150000004677 hydrates Chemical class 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Inorganic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

AT03708319T 2002-02-26 2003-02-24 Neue kristalline formen der krebsbekämpfenden verbindung zd1839 ATE465738T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB0204392A GB0204392D0 (en)	2002-02-26	2002-02-26	Pharmaceutical compound
GB0212462A GB0212462D0 (en)	2002-05-30	2002-05-30	Pharmaceutical compound
PCT/GB2003/000794 WO2003072108A1 (en)	2002-02-26	2003-02-24	Novel crystalline forms of the anti-cancer compound zd1839

Publications (1)

Publication Number	Publication Date
ATE465738T1 true ATE465738T1 (de)	2010-05-15

Family

ID=27767099

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT03708319T ATE465738T1 (de)	2002-02-26	2003-02-24	Neue kristalline formen der krebsbekämpfenden verbindung zd1839

Country Status (16)

Country	Link
US (2)	US7612077B2 (de)
EP (1)	EP1480650B1 (de)
JP (1)	JP4836404B2 (de)
KR (1)	KR20040086452A (de)
CN (1)	CN100404032C (de)
AT (1)	ATE465738T1 (de)
AU (1)	AU2003212500B2 (de)
BR (1)	BRPI0308023B1 (de)
CA (3)	CA2833470C (de)
DE (1)	DE60332322D1 (de)
ES (1)	ES2342660T3 (de)
IL (2)	IL163689A0 (de)
MX (1)	MXPA04008330A (de)
NO (1)	NO329618B1 (de)
NZ (1)	NZ534871A (de)
WO (1)	WO2003072108A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BRPI0307786B8 (pt) *	2002-02-26	2021-05-25	Astrazeneca Ab	composição farmacêutica, método para preparar a mesma, métodos para inibir a taxa de precipitação do agente da solução no trato gi, e para reduzir variabilidade inter-pacientes no que se refere à biodisponibilidade e/ou concentrações plásmáticas do agente, e, uso de um celulose éter solúvel em água ou de um éster de um celulose éter solúvel em água
GB0317663D0 (en) *	2003-07-29	2003-09-03	Astrazeneca Ab	Pharmaceutical composition
WO2006090413A1 (en) *	2005-02-23	2006-08-31	Natco Pharma Limited	Novel crystalline form of gefitinib and a process for its preparation
TWI366460B (en) *	2005-06-16	2012-06-21	Euro Celtique Sa	Cannabinoid active pharmaceutical ingredient for improved dosage forms
US9980765B2 (en)	2010-02-15	2018-05-29	The General Hospital Corporation	Methods and devices for selective disruption of visceral fat by controlled cooling
CN101973944B (zh) *	2010-10-14	2012-07-04	江苏先声药物研究有限公司	一种Gefitinib Form 1 晶型的制备方法
UA113500C2 (xx)	2010-10-29	2017-02-10		Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
CA3152557A1 (en)	2010-10-29	2012-05-03	Abbvie Inc.	Solid dispersions containing an apoptosis-inducing agent
ES2603129T3 (es)	2010-11-23	2017-02-23	Abbvie Ireland Unlimited Company	Métodos de tratamiento utilizando inhibidores selectivos de Bcl-2
PT2643322T (pt)	2010-11-23	2017-11-13	Abbvie Inc	Sais e formas cristalinas de um agente indutor de apoptose
US8395552B2 (en)	2010-11-23	2013-03-12	Metamagnetics, Inc.	Antenna module having reduced size, high gain, and increased power efficiency
CN103319422B (zh) *	2012-03-21	2016-05-04	石药集团中奇制药技术（石家庄）有限公司	一种吉非替尼晶型及其制备方法
WO2014016848A2 (en)	2012-07-24	2014-01-30	Laurus Labs Private Limited	Solid forms of tyrosine kinase inhibitors, process for the preparation and their pharmaceutical composition thereof
CN103896862B (zh) *	2012-12-25	2017-05-10	江苏天士力帝益药业有限公司	一种吉非替尼Form 1晶型的制备方法
CN103896863B (zh) *	2012-12-26	2017-06-13	亚宝药业集团股份有限公司	抗癌化合物zd1839的晶型及其制备方法
CN103896861A (zh) *	2012-12-26	2014-07-02	亚宝药业集团股份有限公司	抗癌化合物zd1839的无定形物及其制备方法
CN103910690A (zh) *	2013-01-06	2014-07-09	上海科胜药物研发有限公司	一种吉非替尼新晶型及其制备方法
CN103102316A (zh) *	2013-01-17	2013-05-15	李彦	ZD1839Form 1晶型的制备方法
US20140275082A1 (en)	2013-03-14	2014-09-18	Abbvie Inc.	Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
CN103360326B (zh) *	2013-04-19	2016-03-30	南京优科生物医药研究有限公司	吉非替尼晶型i的精制方法
US20140357723A1 (en) *	2013-05-29	2014-12-04	Uwe-Bernd Bernd Ross	Tricholine Nasal Formulation and Method of Use
KR20150001936A (ko) *	2013-06-28	2015-01-07	제일약품주식회사	게피티닙의 신규한 결정형 및 이의 제조방법
WO2015170345A1 (en)	2014-05-09	2015-11-12	Council Of Scientific & Industrial Research	Pharmaceutical cocrystals of gefitinib
US11504322B2 (en)	2014-08-28	2022-11-22	The General Hospital Corporation	Injectable slurries and methods of manufacturing the same
US11471401B2 (en)	2014-08-28	2022-10-18	The General Hospital Corporation	Injectable slurries and methods of manufacturing the same
CA2958768C (en) *	2014-08-28	2023-08-29	The General Hospital Corporation	Injectable slurries and methods of manufacturing and using the same
CN104277005A (zh) *	2014-09-19	2015-01-14	成都新恒创药业有限公司	一种吉非替尼Form 1晶型的制备方法
US20180000827A1 (en)	2014-12-19	2018-01-04	Synthon B.V.	Pharmaceutical composition comprising gefitinib
ES2851499T3 (es) *	2015-12-30	2021-09-07	Synthon Bv	Proceso para fabricar una forma cristalina de gefitinib
US11564830B2 (en)	2016-02-26	2023-01-31	The General Hospital Corporation	Medical ice slurry production and delivery systems and methods
CN106083739B (zh) *	2016-05-31	2019-05-14	华南理工大学	吉非替尼新晶型及其基于超临界反溶剂技术的制备方法
CN111454221B (zh) *	2020-04-21	2023-01-06	华南理工大学	一种吉非替尼和布美他尼药物共晶体及其制备方法
CN118221596A (zh) *	2020-06-15	2024-06-21	山东新时代药业有限公司	一种吉非替尼的有机酸盐
US11241330B1 (en)	2021-04-02	2022-02-08	Brixton Biosciences, Inc.	Apparatus for creation of injectable slurry

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9300059D0 (en)	1992-01-20	1993-03-03	Zeneca Ltd	Quinazoline derivatives
GB9508538D0 (en)	1995-04-27	1995-06-14	Zeneca Ltd	Quinazoline derivatives
GB0008368D0 (en)	2000-04-06	2000-05-24	Astrazeneca Ab	Combination product
BRPI0307786B8 (pt)	2002-02-26	2021-05-25	Astrazeneca Ab	composição farmacêutica, método para preparar a mesma, métodos para inibir a taxa de precipitação do agente da solução no trato gi, e para reduzir variabilidade inter-pacientes no que se refere à biodisponibilidade e/ou concentrações plásmáticas do agente, e, uso de um celulose éter solúvel em água ou de um éster de um celulose éter solúvel em água

2003
- 2003-02-24 KR KR10-2004-7013341A patent/KR20040086452A/ko not_active Ceased
- 2003-02-24 AU AU2003212500A patent/AU2003212500B2/en not_active Expired
- 2003-02-24 JP JP2003570854A patent/JP4836404B2/ja not_active Expired - Lifetime
- 2003-02-24 BR BRPI0308023-4A patent/BRPI0308023B1/pt not_active IP Right Cessation
- 2003-02-24 CA CA2833470A patent/CA2833470C/en not_active Expired - Lifetime
- 2003-02-24 DE DE60332322T patent/DE60332322D1/de not_active Expired - Lifetime
- 2003-02-24 EP EP03708319A patent/EP1480650B1/de not_active Expired - Lifetime
- 2003-02-24 MX MXPA04008330A patent/MXPA04008330A/es active IP Right Grant
- 2003-02-24 IL IL16368903A patent/IL163689A0/xx active IP Right Grant
- 2003-02-24 AT AT03708319T patent/ATE465738T1/de not_active IP Right Cessation
- 2003-02-24 CA CA2702297A patent/CA2702297C/en not_active Expired - Lifetime
- 2003-02-24 CN CNB038091623A patent/CN100404032C/zh not_active Expired - Lifetime
- 2003-02-24 CA CA2477350A patent/CA2477350C/en not_active Expired - Lifetime
- 2003-02-24 US US10/505,690 patent/US7612077B2/en not_active Expired - Fee Related
- 2003-02-24 WO PCT/GB2003/000794 patent/WO2003072108A1/en not_active Ceased
- 2003-02-24 ES ES03708319T patent/ES2342660T3/es not_active Expired - Lifetime
- 2003-02-24 NZ NZ534871A patent/NZ534871A/en not_active IP Right Cessation
2004
- 2004-08-23 IL IL163689A patent/IL163689A/en unknown
- 2004-09-24 NO NO20044047A patent/NO329618B1/no not_active IP Right Cessation
2009
- 2009-09-17 US US12/561,835 patent/US20100137304A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP1480650A1 (de)	2004-12-01
CA2833470A1 (en)	2003-09-04
US7612077B2 (en)	2009-11-03
BRPI0308023B1 (pt)	2021-07-27
CA2702297C (en)	2014-02-04
AU2003212500A1 (en)	2003-09-09
CA2477350C (en)	2013-02-12
EP1480650B1 (de)	2010-04-28
NO20044047L (no)	2004-11-16
DE60332322D1 (de)	2010-06-10
CN100404032C (zh)	2008-07-23
CN1652790A (zh)	2005-08-10
NO329618B1 (no)	2010-11-22
US20050209229A1 (en)	2005-09-22
JP2005525354A (ja)	2005-08-25
IL163689A0 (en)	2005-12-18
KR20040086452A (ko)	2004-10-08
WO2003072108A1 (en)	2003-09-04
CA2702297A1 (en)	2003-09-04
HK1070582A1 (en)	2005-06-24
JP4836404B2 (ja)	2011-12-14
NZ534871A (en)	2007-05-31
AU2003212500B2 (en)	2008-01-03
MXPA04008330A (es)	2004-11-26
IL163689A (en)	2011-10-31
ES2342660T3 (es)	2010-07-12
BR0308023A (pt)	2004-12-28
CA2833470C (en)	2016-03-29
CA2477350A1 (en)	2003-09-04
US20100137304A1 (en)	2010-06-03

Legal Events

Date	Code	Title	Description
2010-10-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE465738T1 (de)	2010-05-15	Neue kristalline formen der krebsbekämpfenden verbindung zd1839
CY1113395T1 (el)	2016-06-22	Σταθερη φαρμακευτικη συνθεση που περιεχει πυριμιδινη-σουλφαμιδη
CR8842A (es)	2007-08-28	Derivados de pirido-pirimidina, su preparacion, su aplicacion en terapeutica
MY142018A (en)	2010-08-16	Thiophene derivatives as chk 1 inihibitors
CY1108573T1 (el)	2014-04-09	Ανταγωνιστες νρυυ5
ATE297910T1 (de)	2005-07-15	Retinoid x rezeptormodulatoren
HUP0401982A2 (hu)	2005-01-28	Indolizinszármazékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyászati készítmények
MXPA05009985A (es)	2005-11-04	Ligandos de receptores de canabinoides.
AR022469A1 (es)	2002-09-04	Uso de acidos isoxazolcarboxilicos sustituidos y derivados y nuevas sustancias
BR0206595A (pt)	2004-07-13	Composto, composição farmacêutica, e uso de um composto
MXPA02010627A (es)	2004-05-17	Derivados de 2-acil-indol y su uso como farmaco antitumoral.
NZ547565A (en)	2009-07-31	Substituted arylpyrazoles as parasiticidal agents
UY29169A1 (es)	2006-05-31	Derivados de 2-amido-4 feniltiazol, su preparacion y su aplicacion en terapeutica
TW200603799A (en)	2006-02-01	Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
PA8561501A1 (es)	2003-07-28	Lactamas como antagonistas de taquiquininas
TWI268280B (en)	2006-12-11	Novel farnesyl protein transferase inhibitors as antitumor agents
DE60114640D1 (en)	2005-12-08	Antithrombosemittel
MXPA04006113A (es)	2005-06-08	Derivados de triazoloquinolina utiles como ligandos receptores de adenosina.
AR027559A1 (es)	2003-04-02	Metodo para la preparacion de citalopram
TW200800962A (en)	2008-01-01	Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
ATE341552T1 (de)	2006-10-15	Derivate morphinähnlicher opioidverbindungen
TNSN04105A1 (en)	2006-06-01	Imidazoquinoline derivatives
GEP20074256B (en)	2007-12-10	Novel benzothiadiazine, process for their preparation and pharmaceutical compositions containing
WO2007004041A3 (en)	2007-03-22	New compounds and their pharmaceutical use
HUP0401895A2 (hu)	2004-12-28	Paroxetin N-formil származékai, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények